Durect (DRRX)

[BooDog]

Oral Late-Breaking Presentation Details:


Tarek Hassanein, M.D., one of the trial’s principal investigators, will deliver the oral late-breaking presentation detailing trial results.

Title:

Safety and Efficacy of DUR-928: A Potential New Therapy for Acute Alcoholic Hepatitis


Date: Tuesday, November 12, 2019

Time: 8:30 a.m. Eastern Time

Location: Auditorium, Hynes Convention Center

Session Title: Late-Breaking Abstract Oral Session II

Presentation Type: Oral, Late-Breaking Session

Publication Number: LO9




In a separate poster presentation, Craig McClain, M.D., will present additional comparative data from the Phase 2a clinical trial of DUR-928 and a control group from a contemporaneous AH trial conducted at University of Louisville.


Poster Presentation Details:

Title: DUR-928 Therapy of Acute Alcoholic Hepatitis: A Pilot Study

Date: Sunday, November 10, 2019

Time: 12:00 – 2:00 p.m. Eastern Time

Presentation Type: Poster Presentation

Location: Hynes Convention Center, Hall B

Publication Number: 1376




We've got the cash and ready to rock.


Earnings Conference Call

We will host a conference call today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss third quarter 2019 results and provide a corporate update:




Toll Free:877-407-0784

International:201-689-8560

Conference ID:13695661

Webcast:http://public.viavid.com/index.php?id=136610


https://www.sec.gov/Archives/edgar/data/1082038/000156459019039797/drrx-ex991_6.htm